Extended Data Fig. 9: ESK981 sensitizes the murine breast cancer 4T1 model to anti-PD-1 immunotherapy.
a, Bioluminescent signaling images showing dorsal and ventral views of individual 4T1 tumor-bearing mice from indicated treatment groups. b, Bioluminescent quantification of total tumor burden from individual mice treated with vehicle (n = 5 mice), anti-PD-1 (n = 4 mice), ESK981 15 mg/kg (n = 5 mice), ESK981+anti-PD-1 (n = 5 mice). Data were analyzed by two-tailed unpaired t test and presented as mean ± SEM. P-value indicated. c, Overall survival of 4T1-bearing mice treated with either anti-PD-1 (n = 15 mice) or ESK981 and anti-PD-1 combination (n = 15 mice).
